Sarilumab vs placebo or usual care
All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether sarilumab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).
1 finding from 1 review
- Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes onlyRR 1.06 [0.86, 1.3]9 studies · 3305 participantsVery low